ATLAS Biolabs announces its accreditation as a certified Affymetrix DMET™ Service Provider, offering the latest DMET™ Plus Solution from Affymetrix. ATLAS Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.
Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolizing enzymes and drug transporters. Analyzing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.
DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimization of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.
“DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalized medicine,” says Patrick Kelly, Director of Sales and Market Development at ATLAS Biolabs. “We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way.”
The DMET™ Plus Solution
DMET Plus from Affymetrix includes (a) a molecular inversion probe (MIP) panel to amplify the precise target DNA of interest; (b) an allele-specific oligonucleotide array providing a single-color readout on Affymetrix’s GeneChip System® 3000 or the GeneChip® System 3000Dx v.2; and (c) the DMET analysis software, which offers both flexibility for user-defined reporting and the most comprehensive translation from genotypic data to star-allele classification and to predicted metabolizer status for the most clinically relevant genes. Assay performance is characterized by >99% average sample-call rates and >99.8% average sample reproducibility, which enables the accurate generation of haplotypes and supports longitudinal and other clinical research studies.